CliffBio
small molecule

TUZISTRA XR

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

Loss of exclusivityMarch 2029latest FDA-listed patent expiry
CompanyTris. →View the full company profile on CliffBio

Drug detail

Brand nameTUZISTRA XR
Active ingredientCHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX
StrengthEQ 2.8MG BASE/5ML;EQ 14.7MG BASE/5ML
Dosage formSUSPENSION, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalApril 2015
Marketing statusDISCN

Listed patents

PatentExpiresType
8062667March 2029product
8790700March 2027product

More from Tris.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

TUZISTRA XR patent cliff — loss of exclusivity March 2029 | CliffBio